Spots Global Cancer Trial Database for Study of Pretargeted Radioimmunotherapy of a Anti-CEA Bispecific Antibody and Lu177-labeled Peptide in Colorectal Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of Pretargeted Radioimmunotherapy of a Anti-CEA Bispecific Antibody and Lu177-labeled Peptide in Colorectal Cancer
Official Title: Phase I Clinical Study of the Feasibility of Pretargeted Radioimmunotherapy of an Anti-CEA Bispecific Antibody and Lu-177-labeled Peptide in Patients With Advanced Colorectal Cancer
Study ID: NCT00860860
Conditions
Study Description
Brief Summary: This study will investigate the toxicity, safety and pharmacokinetics of pretargeted radioimmunotherapy with anti-CEA x anti-hapten bispecific antibody TF2 and Lu-177-labeled di-HSG-DOTA peptide IMP-288. Furthermore, the sensitivity of pretargeted imaging with In-111-labeled IMP-288 as compared to standard methods of tumor detection, and the preliminary efficacy of the therapy.
Detailed Description: Pretherapy cycle with IMP-288 labeled In111.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Radboud University Nijmegen Medical Centre, Nijmegen, , Netherlands
Contact Details
Name: O C Boerman, PhD
Affiliation: RUNMC Department of Nuclear Medicine
Role: STUDY_CHAIR
Name: R Schoffelen, MD
Affiliation: RUNMC Department of Nuclear Medicine
Role: STUDY_CHAIR
Name: W JG Oyen, MD PhD
Affiliation: RUNMC Department of Nuclear Medicine
Role: PRINCIPAL_INVESTIGATOR
Name: W TA van der Graaf, MD PhD
Affiliation: RUNMC Department of Medical Oncology
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
